Analysis of the factors predicting clinical response to tocilizumab therapy in patients with severe COVID-19

Analysis of the factors predicting clinical response to tocilizumab therapy in patients with severe COVID-19

Background: Controversy remains about the efficacy of tocilizumab (TCZ) for the treatment of severe COVID-19. We aimed to analyze the profile of TCZ-respondent patients. Methods: We retrospectively analyzed a cohort of patients with severe COVID-19 who received off-label TCZ after recommendation by...

Full description

Bibliographic Details
Main Authors: Rafael San-Juan, Mario Fernández-Ruiz, Francisco López-Medrano, Octavio Carretero, Antonio Lalueza, Guillermo Maestro de la Calle, María Asunción Pérez-Jacoiste Asín, Héctor Bueno, José Manuel Caro-Teller, Mercedes Catalán, Cristina de la Calle, Rocío García-García, Carlos Gómez, Rocío Laguna-Goya, Manuel Lizasoáin, Joaquín Martínez-López, Julia Origüen, Ángel Sevillano, Eduardo Gutiérrez, Borja de Miguel, Fernando Aguilar, Patricia Parra, Mar Ripoll, Tamara Ruiz-Merlo, Hernando Trujillo, José Luis Pablos, Estela Paz-Artal, Carlos Lumbreras, José María Aguado
Format: Article
Language:English
Published: Elsevier 2022-04-01
Series:International Journal of Infectious Diseases
Subjects:
COVID-19
tocilizumab
clinical response
predictors
early initiation
Online Access:http://www.sciencedirect.com/science/article/pii/S1201971222000509

Internet

http://www.sciencedirect.com/science/article/pii/S1201971222000509

Similar Items